

References

I-89

1. Micromedex DrugDex Compendium®. 2024. Carboplatin.
2. Clinical Pharmacology™ Compendia. 2024. Tampa FL: Gold Standard, Inc. Carboplatin.
3. Paraplatin (carboplatin) injection, for intravenous use [package insert]. Bristol-Myers Squibb Company. Princeton, NJ. Revised 07/2010.
4. National Comprehensive Cancer Network (NCCN). NCCN Drugs and Biologics Compendium®. Carboplatin. 2024.
5. Ye Q, Lin J, Feng J. The effects of carboplatin and etoposide on advanced small cell lung cancer and serum tumor markers in correlation with long-term survival rate. *Pakistan Journal Of Pharmaceutical Sciences*. 2018;31(6):2779-2782.
6. Megias-Vericat JE, Martinez-Cuadron D, Sanz MA, et al. Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review. *Annals of Hematology*. 2018;97:1115-1153.
7. Tollkuci E, Chalmers A, Schultz K, et al. Clinical outcomes using carboplatin desensitization in patients with gynecologic cancer. *J Hematol Oncol Pharm*. 2020;10(2):65-72.
8. Takayama K, Takeshita M, Inoue K, et al. Randomized phase II study of first-line biweekly gemcitabine and carboplatin versus biweekly gemcitabine and carboplatin plus maintenance gemcitabine in elderly patients with untreated non-small cell lung cancer: LOGIK0801. *The Oncologist*. 2020;25:1146-1157.
9. Carboplatin In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated January 1, 2009.